Immunotherapy
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411 Watch the “What this Means” segment here Excerpt from the Press Release: PRINCETON, NJ, Nov. 12, 2024 (GLOBE NEWSWIRE)…
Read More
Treatment with STK-012 monotherapy demonstrates dose-dependent induction of pro-inflammatory cytokines and selective proliferation of antigen-activated T cells, along with significant expansion of TCR clonality Company will also present new preclinical and GLP toxicology data on STK-026, its biased IL-12 partial agonist also designed for preferential activity on antigen-activated T cells Excerpt from the Press Release:…
Read More
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes multiple dose treatment of UC patients; Global UC market is expected…
Read More
– GMAB ADC demonstrated highly targeted delivery to tumor cells and durable tumor regression in preclinical model of colorectal cancer – – Results presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 – Excerpt from the Press Release: HOPEWELL, N.J.–(BUSINESS WIRE)–Gennao Bio, a privately held genetic medicines company developing…
Read More
Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase…
Read More
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the continued clinical advancement of TIDAL-01, Turnstone’s lead Selected TIL therapy, currently being evaluated in two Phase 1 trials Results also demonstrate the potential for a streamlined and…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215’s profile as a potential long-acting therapy for hereditary angioedema (HAE) dosed once every three…
Read More
– Combination therapy cohort initiated in Palleon’s ongoing study to evaluate safety, pharmacodynamic effects, and antitumor activity of its lead glyco-immunology candidate in patients with advanced cancer – E-602 being evaluated in combination with cemiplimab (Libtayo®) as part of clinical trial supply agreement with Regeneron Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a…
Read More
Study is the Second Clinical Human Trial Using Mobetron with Electron Excerpt from the Press Release: SUNNYVALE, Calif.–(BUSINESS WIRE)–IntraOp Medical Corporation announced the world’s first Phase II Electron FLASH Trial. It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC). It is the second…
Read More
Excerpt from the Press Release: BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful safety review of the 10 mg dry powder dose safety cohort from the…
Read More